Vessel abnormalization: Another hallmark of cancer?. Molecular mechanisms and therapeutic implications

Current Opinion in Genetics and Development

Volumn 21, Issue 1, 2011, Pages 73-79

  De Bock, Katrien ^a,b   Cauwenberghs, Sandra ^a,b   Carmeliet, Peter ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79551615157     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2010.10.008     Document Type: Review

References (64)

1. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
2. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res 1988, 48:2641-2658.
3. De Bock K., De Smet F., Leite De Oliveira R., Anthonis K., Carmeliet P. Endothelial oxygen sensors regulate tumor vessel abnormalization by instructing phalanx endothelial cells. J Mol Med 2009, 87:561-569.
4. Mazzone M., Dettori D., Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., Tian Y.M., Lanahan A.A., Pollard P., Ruiz de Almodovar C., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
5. Rapisarda A., Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 2009, 12:74-80.
6. Lunt S.J., Chaudary N., Hill R.P. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009, 26:19-34.
7. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010, 21:21-26.
8. Heath V.L., Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009, 6:395-404.
9. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
10. Horowitz A., Simons M. Branching morphogenesis. Circ Res 2008, 103:784-795.
11. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
12. Crawford Y., Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009, 335:261-269.
13. Abramovitch R., Dafni H., Smouha E., Benjamin L.E., Neeman M. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 1999, 59:5012-5016.
14. Dickson P.V., Hamner J.B., Sims T.L., Fraga C.H., Ng C.Y., Rajasekeran S., Hagedorn N.L., McCarville M.B., Stewart C.F., Davidoff A.M. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007, 13:3942-3950.
15. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-3736.
16. Franco M., Man S., Chen L., Emmenegger U., Shaked Y., Cheung A.M., Brown A.S., Hicklin D.J., Foster F.S., Kerbel R.S. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006, 66:3639-3648.
17. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di Tomaso E., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
18. Greenberg J.I., Shields D.J., Barillas S.G., Acevedo L.M., Murphy E., Huang J., Scheppke L., Stockmann C., Johnson R.S., Angle N., et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008, 456:809-813.
19. Stockmann C., Doedens A., Weidemann A., Zhang N., Takeda N., Greenberg J.I., Cheresh D.A., Johnson R.S. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-818.
20. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
21. Kamoun W.S., Ley C.D., Farrar C.T., Duyverman A.M., Lahdenranta J., Lacorre D.A., Batchelor T.T., di Tomaso E., Duda D.G., Munn L.L., et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009, 27:2542-2552.
22. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
23. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat Rev Cancer 2008, 8:942-956.
24. Bais C., Wu X., Yao J., Yang S., Crawford Y., McCutcheon K., Tan C., Kolumam G., Vernes J.M., Eastham-Anderson J., et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010, 141:166-177.
25. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
26. Van de Veire S., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., Loges S., Albrecht I., Jonckx B., Vinckier S., et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141:178-190.
27. Rolny C, Mazzone M, Tugues S, Laoui D, Johannson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, et al.: HRG inhibits tumor growth and metastasis by skewing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2010, (in press).
28. Gaengel K., Genove G., Armulik A., Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009, 29:630-638.
29. Furuhashi M., Sjoblom T., Abramsson A., Ellingsen J., Micke P., Li H., Bergsten-Folestad E., Eriksson U., Heuchel R., Betsholtz C., et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res 2004, 64:2725-2733.
30. McCarty M.F., Somcio R.J., Stoeltzing O., Wey J., Fan F., Liu W., Bucana C., Ellis L.M. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007, 117:2114-2122.
31. Hellberg C., Ostman A., Heldin C.H. PDGF and vessel maturation. Recent Results Cancer Res 2010, 180:103-114.
32. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111:1287-1295.
33. Nisancioglu M.H., Betsholtz C., Genove G. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res 2010, 70:5109-5115.
34. Gerhardt H., Semb H. Pericytes: gatekeepers in tumour cell metastasis?. J Mol Med 2008, 86:135-144.
35. Augustin H.G., Koh G.Y., Thurston G., Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009, 10:165-177.
36. Thurston G., Rudge J.S., Ioffe E., Zhou H., Ross L., Croll S.D., Glazer N., Holash J., McDonald D.M., Yancopoulos G.D. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000, 6:460-463.
37. Saharinen P., Eklund L., Miettinen J., Wirkkala R., Anisimov A., Winderlich M., Nottebaum A., Vestweber D., Deutsch U., Koh G.Y., et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 2008, 10:527-537.
38. Stoeltzing O., Ahmad S.A., Liu W., McCarty M.F., Wey J.S., Parikh A.A., Fan F., Reinmuth N., Kawaguchi M., Bucana C.D., et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 2003, 63:3370-3377.
39. Falcon B.L., Hashizume H., Koumoutsakos P., Chou J., Bready J.V., Coxon A., Oliner J.D., McDonald D.M. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009, 175:2159-2170.
40. Nasarre P., Thomas M., Kruse K., Helfrich I., Wolter V., Deppermann C., Schadendorf D., Thurston G., Fiedler U., Augustin H.G. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 2009, 69:1324-1333.
41. Helfrich I., Edler L., Sucker A., Thomas M., Christian S., Schadendorf D., Augustin H.G. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009, 15:1384-1392.
42. Koh Y.J., Kim H.Z., Hwang S.I., Lee J.E., Oh N., Jung K., Kim M., Kim K.E., Kim H., Lim N.K., et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 2010, 18:171-184.
43. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008, 30:393-402.
44. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
45. Kearney J.B., Kappas N.C., Ellerstrom C., DiPaola F.W., Bautch V.L. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 2004, 103:4527-4535.
46. Carmeliet P., De Smet F., Loges S., Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 2009, 6:315-326.
47. Le Bras A., Lionneton F., Mattot V., Lelievre E., Caetano B., Spruyt N., Soncin F. HIF-2alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites. Oncogene 2007, 26:7480-7489.
48. Dejana E., Tournier-Lasserve E., Weinstein B.M. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell 2009, 16:209-221.
49. Duan L.J., Zhang-Benoit Y., Fong G.H. Endothelium-intrinsic requirement for Hif-2alpha during vascular development. Circulation 2005, 111:2227-2232.
50. Yamashita T., Ohneda K., Nagano M., Miyoshi C., Kaneko N., Miwa Y., Yamamoto M., Ohneda O., Fujii-Kuriyama Y. HIF-2alpha in endothelial cells regulates tumor neovascularization through activation of ephrin A1. J Biol Chem 2008, 283:18926-18936.
51. Skuli N., Liu L., Runge A., Wang T., Yuan L., Patel S., Iruela-Arispe L., Simon M.C., Keith B. Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood 2009, 114:469-477.
52. Chen J.X., Stinnett A. Ang-1 gene therapy inhibits hypoxia-inducible factor-1alpha (HIF-1alpha)-prolyl-4-hydroxylase-2, stabilizes HIF-1alpha expression, and normalizes immature vasculature in db/db mice. Diabetes 2008, 57:3335-3343.
53. Fraisl P., Mazzone M., Schmidt T., Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev Cell 2009, 16:167-179.
54. Phng L.K., Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009, 16:196-208.
55. Ridgway J., Zhang G., Wu Y., Stawicki S., Liang W.C., Chanthery Y., Kowalski J., Watts R.J., Callahan C., Kasman I., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444:1083-1087.
56. Noguera-Troise I., Daly C., Papadopoulos N.J., Coetzee S., Boland P., Gale N.W., Lin H.C., Yancopoulos G.D., Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444:1032-1037.
57. Li J.L., Sainson R.C., Shi W., Leek R., Harrington L.S., Preusser M., Biswas S., Turley H., Heikamp E., Hainfellner J.A., et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007, 67:11244-11253.
58. Yan M., Callahan C.A., Beyer J.C., Allamneni K.P., Zhang G., Ridgway J.B., Niessen K., Plowman G.D. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010, 463:E6-E7.
59. Dou G.R., Wang Y.C., Hu X.B., Hou L.H., Wang C.M., Xu J.F., Wang Y.S., Liang Y.M., Yao L.B., Yang A.G., et al. RBP-J, the transcription factor downstream of Notch receptors, is essential for the maintenance of vascular homeostasis in adult mice. FASEB J 2008, 22:1606-1617.
60. Patel N.S., Dobbie M.S., Rochester M., Steers G., Poulsom R., Le Monnier K., Cranston D.W., Li J.L., Harris A.L. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 2006, 12:4836-4844.
61. Ebos J.M.L., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
62. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
63. Hamzah J., Jugold M., Kiessling F., Rigby P., Manzur M., Marti H.H., Rabie T., Kaden S., Grone H.J., Hammerling G.J., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410-414.
64. Kashiwagi S., Tsukada K., Xu L., Miyazaki J., Kozin S.V., Tyrrell J.A., Sessa W.C., Gerweck L.E., Jain R.K., Fukumura D. Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med 2008, 14:255-257.